{"gene":"SMUG1","run_date":"2026-06-10T07:46:36","timeline":{"discoveries":[{"year":2001,"finding":"SMUG1 was identified as the major uracil-DNA glycosylase activity in UNG-deficient mice, functioning as the primary backup enzyme for repair of deaminated cytosine. SMUG1 is present at similar levels in non-proliferating and proliferating tissues, indicating a replication-independent role in DNA repair, distinct from UNG which localizes to replication foci.","method":"Specific neutralizing antibodies used to identify SMUG1 activity in Ung-/- mouse cells and tissues; subcellular localization by cell fractionation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal antibody neutralization assay in knockout mice, replicated finding consistent with genetic knockout data from multiple labs","pmids":["11483530"],"is_preprint":false},{"year":2001,"finding":"Human SMUG1 (hSMUG1) was identified as identical to HMUDG (5-hydroxymethyluracil DNA N-glycosylase), demonstrating that SMUG1 excises 5-hydroxymethyluracil (5hmUra) from DNA with ~20x the specific activity of the most purified bovine HMUDG fraction.","method":"Protein purification from calf thymus, SDS-PAGE renaturation assay, mass spectrometry peptide identification, recombinant GST-fusion protein expression and in vitro enzymatic assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with recombinant protein plus mass spectrometry identification, rigorous biochemical characterization","pmids":["11526119"],"is_preprint":false},{"year":2003,"finding":"Crystal structure of SMUG1 complexed with DNA and base-excision products revealed a more invasive interaction with dsDNA than other UDGs, and an elegant water displacement/replacement mechanism that allows SMUG1 to exclude thymine while accepting 5-hydroxymethyluracil (HmU) as a substrate. SMUG1 is specialized for antimutational uracil excision and also excises the oxidation-damage product HmU.","method":"X-ray crystallography of SMUG1-DNA complex","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with bound substrate/product providing direct mechanistic insight into substrate discrimination","pmids":["12820976"],"is_preprint":false},{"year":2003,"finding":"Rat and human SMUG1 excise 5-formyluracil (fU), uracil (U), 5-hydroxyuracil (hoU), and 5-hydroxymethyluracil (hmU) from both single-stranded and double-stranded DNA, but not analogous cytosine derivatives (5-hydroxycytosine, 5-formylcytosine) or other oxidized damage. hSMUG1 antibodies neutralized fU, hmU, and hoU activities in HeLa cell extracts, confirming SMUG1 is the primary repair enzyme for this subset of oxidized pyrimidines.","method":"Recombinant protein expression of rat and human SMUG1, in vitro substrate specificity assays with various modified bases in ss and dsDNA, antibody neutralization of HeLa cell extract activity","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant enzymes plus antibody neutralization in cell extracts, multiple orthogonal methods","pmids":["12718543"],"is_preprint":false},{"year":2004,"finding":"Site-directed mutagenesis of hSMUG1 identified crucial residues for catalysis and damage recognition: Asn85 and His239 are required for N-glycosidic bond hydrolysis; Phe98 mediates pi-pi stacking discrimination of pyrimidine rings; Asn163 forms specific hydrogen bonds to the Watson-Crick face of the base; and Gly87-Met91 loop enables recognition of C5 substituents through water-bridged (uracil) or direct (hoU, hmU, fU) hydrogen bonds.","method":"Site-directed mutagenesis of hSMUG1 combined with in vitro activity assays for multiple substrates (U, hoU, hmU, fU) and homology modeling based on Xenopus laevis SMUG1 structure","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — active-site mutagenesis with functional validation for multiple residues across multiple substrates, supported by structural modeling","pmids":["15466595"],"is_preprint":false},{"year":2005,"finding":"siRNA-mediated silencing of Smug1 in mouse embryo fibroblasts generates a mutator phenotype with increased C:G to T:A transitions. Cells deficient in both Smug1 and Ung show an additive 10-fold increase in spontaneous C:G to T:A transitions at non-CpG sites, demonstrating that these enzymes have distinct and non-redundant roles. Smug1-deficient cells are also hypersensitive to ionizing radiation, revealing a role of SMUG1 in repair of oxidative cytosine lesions.","method":"Stable siRNA-mediated knockdown of Smug1, spontaneous mutation frequency measurement (lacZ reporter), double-mutant epistasis analysis (Ung-/- Smug1 knockdown), ionizing radiation sensitivity assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with loss-of-function and defined mutational phenotype, double-mutant analysis across two independent labs","pmids":["15902269"],"is_preprint":false},{"year":2006,"finding":"SMUG1, if overexpressed, can partially substitute for UNG in antibody diversification (somatic hypermutation and class switch recombination), but SMUG1 plays little natural role in antibody diversification because it is diminishingly expressed during B-cell activation. Even when overexpressed, SMUG1 favors conventional repair of U:G lesions rather than diversification, distinguishing it from UNG which associates with replication sites.","method":"SMUG1 overexpression in DT40 B cells and transgenic mice; somatic hypermutation pattern analysis; isotype switching assays in SMUG-transgenic msh2-/- ung-/- mice; expression analysis during B-cell activation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with transgenic overexpression, multiple functional readouts (SHM patterns, isotype switching), consistent with biology from multiple labs","pmids":["16407970"],"is_preprint":false},{"year":2007,"finding":"SMUG1 (but not UNG) excises 5-fluorouracil (FU) incorporated into DNA and protects against FU cytotoxicity. Accumulation of FU in the genome, rather than uracil excision, is the predominant cause of FU cytotoxicity in mammalian cells.","method":"Gene-targeted cell lines defective in UNG, SMUG1, or both; FU cytotoxicity assays; genomic FU/uracil incorporation measurements","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockouts with defined biochemical and cytotoxicity phenotypes, multiple orthogonal methods","pmids":["17283124"],"is_preprint":false},{"year":2007,"finding":"SMUG1 and UNG2 coordinate the initial steps of base excision repair by distinct mechanisms: UNG2 stimulates AP-site cleavage by APE1 and lacks product-binding capacity enabling rapid turnover; SMUG1 binds tightly to AP-sites and inhibits AP-site cleavage by AP-endonucleases. A specific motif important for AP-site product binding was identified in SMUG1; mutations in this motif increase catalytic turnover by reducing product binding.","method":"In vitro AP-site binding and cleavage assays; E. coli complementation assay; site-directed mutagenesis of AP-site binding motif; comparison of UNG2 and SMUG1 enzymatic properties","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis and multiple orthogonal biochemical assays in a single rigorous study","pmids":["17537817"],"is_preprint":false},{"year":2008,"finding":"SMUG1 (bacterial ortholog from Geobacter metallireducens and human SMUG1) are not only uracil-DNA glycosylases but also xanthine DNA glycosylases (XDGs). Mutational analysis identified M57 and H210 as critical for both XDG and UDG activities via interactions with the C2 carbonyl oxygen; G60Y abolishes both activities by blocking base entry to the binding pocket; G63P switches Gme SMUG1 to an exclusive UDG by altering active-site loop flexibility.","method":"Site-directed mutagenesis of bacterial and human SMUG1, in vitro XDG and UDG activity assays on ss and dsDNA substrates, molecular dynamics simulations","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis with in vitro enzymatic reconstitution and MD simulations providing mechanistic insight","pmids":["18835277"],"is_preprint":false},{"year":2012,"finding":"Targeted inactivation of mouse Smug1 ablates nearly all hmU-DNA excision activity in tissue extracts and renders embryo fibroblasts resistant to 5-hydroxymethyldeoxyuridine toxicity. Combined Smug1/Ung knockout leads to loss of nearly all detectable uracil excision activity, confirming SMUG1 as the dominant glycosylase for hmU-excision and major UNG-backup for U-excision in mice.","method":"Knockout mouse generation, biochemical assay of tissue extracts, 5-hydroxymethyldeoxyuridine cytotoxicity assay in embryo fibroblasts, double-knockout epistasis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with biochemical validation and epistasis analysis in multiple tissue types","pmids":["22447450"],"is_preprint":false},{"year":2012,"finding":"SMUG1 is predominantly double-strand-specific under physiological salt conditions (in the presence of Mg2+ and monovalent salts), whereas UNG2 efficiently removes uracil from both ss and dsDNA. Uracil in AID hotspot sequences is removed 200-fold more efficiently from ssDNA by UNG2 than by SMUG1, explaining why SMUG1 cannot replace UNG2 in antibody diversification despite not being excluded from Ig loci.","method":"In vitro UDG activity assays under varying ionic conditions with ss and dsDNA substrates; measurement of sequence preference for AID hotspot sequences","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution with systematic substrate variation, provides mechanistic explanation for prior genetic observations","pmids":["22483865"],"is_preprint":false},{"year":2012,"finding":"SMUG1 interacts with the pseudouridine synthase Dyskerin (DKC1) and colocalizes with DKC1 in nucleoli and Cajal bodies. SMUG1 has enzymatic activity on single-stranded RNA containing 5-hydroxymethyldeoxyuridine. SMUG1 associates with the 47S rRNA precursor, and depletion of SMUG1 reduces mature rRNA levels with concomitant increase in polyadenylated rRNA and accumulation of 5-hydroxymethyluridine in rRNA.","method":"Co-immunoprecipitation (SMUG1-DKC1 interaction), colocalization by immunofluorescence, in vitro RNA glycosylase activity assay, RNA immunoprecipitation (47S rRNA), siRNA depletion with rRNA maturation analysis and 5-hydroxymethyluridine quantification","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vitro RNA activity assay, and functional depletion phenotype with multiple orthogonal methods in one study","pmids":["23246433"],"is_preprint":false},{"year":2012,"finding":"Loss of SMUG1 (but not UNG) leads to >2-fold increased sensitivity to 5-fluorouracil specifically after drug removal (recovery phase), associated with prolonged S-phase arrest, transient increase in DNA double-strand breaks, and altered CHK1 phosphorylation, indicating SMUG1 has a role in resumption of replication following 5-FU treatment.","method":"SMUG1 and UNG knockdown in human cell lines, 5-FU sensitivity assays (continuous vs. 24h then recovery), cell cycle analysis, comet assay, CHK1 phosphorylation by immunoblot","journal":"Mutation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean knockdown with multiple phenotypic readouts but single lab, mechanistic pathway placement by epistasis","pmids":["23253900"],"is_preprint":false},{"year":2014,"finding":"Endogenous SMUG1 contributes to immunoglobulin class switching in Ung-/- mice, with most residual class switching in Ung-/- mice depending on SMUG1. In vitro switching to IgG1 and serum IgG3, IgG2b, and IgA are greatly diminished in Ung-/- Smug1-/- mice. SMUG1 deficiency in an Ung-/- background further reduces somatic hypermutation at A:T base pairs.","method":"Double-knockout mice (Ung-/- Smug1-/-), in vitro class switching assays, serum immunoglobulin isotype quantification, somatic hypermutation pattern analysis","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in double-knockout mice with multiple functional readouts (switching assays, serum isotypes, SHM patterns)","pmids":["24771041"],"is_preprint":false},{"year":2017,"finding":"Pre-steady-state kinetic analysis revealed the mechanism of damaged base recognition by hSMUG1: the enzyme undergoes nonspecific DNA binding followed by specific damaged-base recognition using a 'wedge' strategy for lesion search. SMUG1 is rate-limited by release from the AP-site product (tight product binding confirmed), with the true catalytic rate faster than kcat measured at steady state. Conformational changes in both enzyme (Trp fluorescence) and DNA (2-aminopurine fluorescence and FRET) were detected during recognition.","method":"Stopped-flow fluorescence spectroscopy using Trp fluorescence, 2-aminopurine fluorescence, and FRET with dU:dG DNA substrate; pre-steady-state kinetic analysis","journal":"Molecular bioSystems","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous pre-steady-state kinetics with multiple orthogonal fluorescence methods revealing mechanistic steps of substrate recognition","pmids":["29051947"],"is_preprint":false},{"year":2017,"finding":"In Smug1-/- mice, 5-hydroxymethyluracil accumulates in genomic DNA (up to 26-fold in brain, correlating with 5-hydroxymethylcytosine levels), while uracil does not accumulate. Ung-/- Smug1-/- mice show synergistic uracil accumulation (up to 25-fold). Whole genome sequencing of double-deficient tumors reveals C to T transitions primarily at CpG sequences, identifying mutational signatures of combined UNG/SMUG1 deficiency.","method":"Knockout mice (single and double), genomic 5-hydroxymethyluracil and uracil quantification by mass spectrometry, whole-genome sequencing of tumors for mutational signature analysis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with quantitative biochemical substrate measurement and genome-wide mutation analysis; multiple complementary methods","pmids":["28775312"],"is_preprint":false},{"year":2019,"finding":"SMUG1 interacts with the telomeric RNA component (hTERC) and is required for co-transcriptional processing of nascent hTERC into mature form. SMUG1 regulates base modifications in hTERC in a region between the CR4/CR5 domain and H box; loss of SMUG1 leads to reduced DKC1 binding to hTERC, accumulation of 3'-polyadenylated and 3'-extended hTERC intermediates degraded by an EXOSC10-independent pathway, and telomerase deficiency leading to impaired bone marrow proliferation in Smug1-knockout mice.","method":"RNA immunoprecipitation (SMUG1-hTERC interaction), DKC1-hTERC binding assay in SMUG1-depleted cells, hTERC processing intermediate analysis by northern blot/RT-PCR, telomerase activity assay, Smug1-knockout mouse bone marrow proliferation analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (RIP, binding assays, RNA processing analysis, telomerase activity, in vivo knockout phenotype) in single rigorous study","pmids":["31412240"],"is_preprint":false},{"year":2023,"finding":"UV-DDB (UV-damaged DNA-binding protein, consisting of DDB1 and DDB2 subunits) stimulates SMUG1 excision activity on 5-hmdU substrates by 4-5-fold in vitro, displaces SMUG1 from abasic site products (EMSA), and decreases SMUG1 half-life on DNA ~8-fold (single-molecule analysis). In cells, DDB2 and SMUG1 form discrete co-localizing foci after 5-hmdU treatment and exhibit transient interaction by proximity ligation assay.","method":"In vitro biochemical excision assay with purified proteins, EMSA, single-molecule analysis, immunofluorescence colocalization, proximity ligation assay, siRNA knockdown with poly(ADP-ribose) accumulation readout","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified proteins plus multiple orthogonal cellular validation methods including single-molecule imaging","pmids":["36971122"],"is_preprint":false}],"current_model":"SMUG1 is a base excision repair glycosylase that excises uracil, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-formyluracil, and 5-fluorouracil from DNA (primarily double-stranded) via a wedge-based lesion search mechanism, with tight AP-site product binding that inhibits APE1 and limits turnover; it also acts on RNA substrates, interacts with the DKC1 pseudouridine synthase to regulate rRNA quality control and hTERC maturation for telomerase biogenesis, is stimulated by UV-DDB during 5-hmdU repair, and plays non-redundant roles with UNG in suppressing C-to-T mutagenesis, processing 5-FU incorporated into DNA, and contributing to immunoglobulin class switching as a backup to UNG."},"narrative":{"mechanistic_narrative":"SMUG1 is a base excision repair DNA glycosylase that initiates antimutational removal of uracil and oxidized pyrimidines, serving as the principal replication-independent backup to UNG for repair of deaminated cytosine [PMID:11483530, PMID:15902269]. It excises uracil, 5-hydroxymethyluracil, 5-hydroxyuracil, and 5-formyluracil from DNA, while excluding thymine and analogous cytosine derivatives, and additionally acts as a xanthine-DNA glycosylase [PMID:11526119, PMID:12718543, PMID:18835277]. Crystallography and active-site mutagenesis define how SMUG1 reads the lesion: an invasive interaction with double-stranded DNA, a water displacement/replacement strategy that admits C5-substituted uracils but excludes thymine, and defined catalytic and recognition residues (Asn85, His239, Phe98, Asn163, and the Gly87-Met91 loop) [PMID:12820976, PMID:15466595]. Pre-steady-state kinetics establish a wedge-based lesion-search mechanism in which catalysis is rate-limited by tight binding to the abasic-site product, a property that lets SMUG1 inhibit AP-site cleavage by APE1 and that distinguishes it from rapid-turnover UNG2 [PMID:17537817, PMID:29051947]; under physiological salt SMUG1 is predominantly double-strand specific, explaining its limited capacity to substitute for UNG in single-strand contexts [PMID:22483865]. Genetically, SMUG1 and UNG have non-redundant roles in suppressing C-to-T mutagenesis and in preventing genomic accumulation of 5-hydroxymethyluracil, with combined deficiency producing synergistic uracil accumulation and CpG-biased mutational signatures [PMID:15902269, PMID:22447450, PMID:28775312]. SMUG1 also processes 5-fluorouracil incorporated into DNA, protecting against its cytotoxicity and supporting replication recovery after drug exposure [PMID:17283124, PMID:23253900], and contributes to immunoglobulin class switching and A:T somatic hypermutation as a backup to UNG [PMID:16407970, PMID:24771041]. Beyond DNA, SMUG1 functions in RNA quality control through interaction with the pseudouridine synthase DKC1, governing rRNA maturation and co-transcriptional processing of the telomerase RNA component hTERC required for telomerase biogenesis [PMID:23246433, PMID:31412240]. Its 5-hmdU excision is stimulated by UV-DDB, which displaces SMUG1 from abasic products to relieve product inhibition [PMID:36971122].","teleology":[{"year":2001,"claim":"Established SMUG1 as the major UNG-independent uracil-excision activity in vivo, defining a replication-independent backup arm of cytosine-deamination repair distinct from replication-coupled UNG.","evidence":"Antibody neutralization of glycosylase activity in Ung-/- mouse cells and subcellular fractionation","pmids":["11483530"],"confidence":"High","gaps":["Did not define the full lesion spectrum","Did not establish whether the backup role suffices to prevent mutagenesis"]},{"year":2001,"claim":"Identified SMUG1 as the enzyme behind HMUDG activity, extending its substrate range beyond uracil to the oxidation product 5-hydroxymethyluracil.","evidence":"Protein purification, mass spectrometry, and recombinant enzyme assays from calf thymus/human SMUG1","pmids":["11526119"],"confidence":"High","gaps":["Did not establish in vivo importance of hmU excision","Strandedness preference not resolved"]},{"year":2003,"claim":"Resolved the structural basis for substrate discrimination, showing how SMUG1 excludes thymine yet accepts C5-modified uracils via a water displacement mechanism and an unusually invasive dsDNA interaction.","evidence":"X-ray crystallography of SMUG1-DNA base-excision product complex; recombinant rat/human enzyme substrate-specificity assays with antibody neutralization in HeLa extracts","pmids":["12820976","12718543"],"confidence":"High","gaps":["Catalytic residue assignments not yet functionally tested","Kinetics of recognition and product release unresolved"]},{"year":2004,"claim":"Defined the catalytic and recognition residues, mechanistically explaining how SMUG1 hydrolyzes the glycosidic bond and reads diverse C5 substituents.","evidence":"Site-directed mutagenesis of hSMUG1 with multi-substrate activity assays and homology modeling","pmids":["15466595"],"confidence":"High","gaps":["Did not address product binding/turnover kinetics","Modeling rather than human crystal structure"]},{"year":2005,"claim":"Demonstrated that SMUG1 and UNG are genetically non-redundant in suppressing C-to-T transitions and that SMUG1 also defends against oxidative cytosine lesions.","evidence":"Stable siRNA knockdown in mouse fibroblasts, lacZ mutation frequency, Ung-/- double-mutant epistasis, and ionizing-radiation sensitivity","pmids":["15902269"],"confidence":"High","gaps":["Knockdown rather than complete knockout","Molecular identity of the relevant oxidative cytosine lesion not defined"]},{"year":2006,"claim":"Clarified why SMUG1 contributes little to antibody diversification under physiological conditions despite being able to substitute for UNG when overexpressed.","evidence":"SMUG1 overexpression in DT40 cells and transgenic mice; SHM/class-switch assays and B-cell expression analysis","pmids":["16407970"],"confidence":"High","gaps":["Did not resolve the biochemical basis for the preference for conventional repair","Endogenous contribution in Ung-/- not yet quantified"]},{"year":2007,"claim":"Showed SMUG1 uniquely processes genomic 5-fluorouracil and that genomic FU incorporation, not uracil excision, drives FU cytotoxicity, linking SMUG1 to chemotherapy response.","evidence":"Gene-targeted UNG/SMUG1/double-deficient cell lines, FU cytotoxicity assays, and genomic FU/uracil measurements","pmids":["17283124"],"confidence":"High","gaps":["Downstream repair steps after FU excision not defined","Did not address replication recovery dynamics"]},{"year":2007,"claim":"Defined the divergent BER initiation logic of SMUG1 versus UNG2, showing SMUG1 binds AP-site products tightly and inhibits APE1 cleavage while UNG2 promotes rapid turnover.","evidence":"In vitro AP-site binding/cleavage assays, E. coli complementation, and mutagenesis of an AP-site-binding motif","pmids":["17537817"],"confidence":"High","gaps":["Cellular factors relieving product inhibition not identified","Physiological consequence of APE1 inhibition unresolved"]},{"year":2008,"claim":"Extended SMUG1's catalytic repertoire to xanthine excision and mapped the active-site determinants distinguishing UDG from XDG activity.","evidence":"Mutagenesis of bacterial and human SMUG1, in vitro UDG/XDG assays, and molecular dynamics simulations","pmids":["18835277"],"confidence":"High","gaps":["In vivo relevance of xanthine excision not established","Frequency of xanthine lesions in genomic DNA not addressed"]},{"year":2012,"claim":"Genetic ablation in mice confirmed SMUG1 as the dominant hmU-excising glycosylase and the major UNG backup for uracil, validating prior biochemical assignments in vivo.","evidence":"Single and double Smug1/Ung knockout mice, tissue extract glycosylase assays, and 5-hmdU cytotoxicity in fibroblasts","pmids":["22447450"],"confidence":"High","gaps":["Did not quantify genomic lesion accumulation","Tissue-specific contributions not resolved"]},{"year":2012,"claim":"Provided the biochemical explanation for SMUG1's limited role at Ig loci by showing it is predominantly double-strand specific under physiological salt, unlike UNG2 on ssDNA.","evidence":"In vitro UDG assays under varying ionic conditions with ss/dsDNA and AID-hotspot substrates","pmids":["22483865"],"confidence":"High","gaps":["Did not test whether cellular cofactors alter strand preference","In vivo strand context at lesion sites not measured"]},{"year":2012,"claim":"Revealed an RNA-directed function for SMUG1 in ribosomal RNA quality control via interaction with DKC1, expanding its role beyond DNA repair.","evidence":"Reciprocal Co-IP and colocalization with DKC1, in vitro ssRNA glycosylase assay, 47S rRNA RIP, and siRNA depletion with rRNA maturation/5-hmU readouts","pmids":["23246433"],"confidence":"High","gaps":["Direct RNA substrate base in vivo not pinpointed","Mechanistic coupling between glycosylase activity and rRNA processing unclear"]},{"year":2012,"claim":"Linked SMUG1 to replication recovery after 5-FU exposure, distinguishing a recovery-phase role from acute uracil/FU excision.","evidence":"SMUG1/UNG knockdown in human cells, recovery-phase FU sensitivity, cell-cycle and comet assays, and CHK1 phosphorylation immunoblot","pmids":["23253900"],"confidence":"Medium","gaps":["Single lab, knockdown only","Mechanistic link between SMUG1 and CHK1/replication checkpoint not established"]},{"year":2014,"claim":"Quantified SMUG1's endogenous contribution to immunoglobulin class switching and A:T hypermutation as the principal residual activity in Ung-/- mice.","evidence":"Ung-/- Smug1-/- double-knockout mice, in vitro switching assays, serum isotype quantification, and SHM pattern analysis","pmids":["24771041"],"confidence":"High","gaps":["Did not define the molecular step at which SMUG1 acts in switching","Strand-specific processing at switch regions not resolved"]},{"year":2017,"claim":"Defined the kinetic mechanism of lesion recognition, establishing a wedge-based search and product-release-limited catalysis with detectable enzyme and DNA conformational changes.","evidence":"Stopped-flow Trp/2-aminopurine fluorescence and FRET pre-steady-state kinetics on dU:dG DNA","pmids":["29051947"],"confidence":"High","gaps":["Did not identify factors that accelerate product release in cells","Recognition kinetics for oxidized substrates not measured"]},{"year":2017,"claim":"Established the in vivo lesion-specific consequences of SMUG1 loss, with selective genomic 5-hmU accumulation and synergistic uracil buildup and CpG-biased mutational signatures upon combined UNG loss.","evidence":"Single/double knockout mice, mass-spectrometric genomic lesion quantification, and whole-genome sequencing of tumors","pmids":["28775312"],"confidence":"High","gaps":["Origin of CpG-biased mutations not mechanistically dissected","Tissue-specific tumor risk not quantified"]},{"year":2019,"claim":"Extended the RNA role to telomerase biogenesis, showing SMUG1 is required for co-transcriptional hTERC processing and DKC1 binding, with telomerase deficiency and impaired bone marrow proliferation on its loss.","evidence":"hTERC RIP, DKC1-hTERC binding in SMUG1-depleted cells, processing-intermediate analysis, telomerase activity assays, and Smug1-knockout mouse bone marrow phenotype","pmids":["31412240"],"confidence":"High","gaps":["Whether catalytic glycosylase activity is required for hTERC processing unresolved","Identity of the modified bases regulating hTERC not fully defined"]},{"year":2023,"claim":"Identified UV-DDB as a stimulatory partner that relieves SMUG1 product inhibition during 5-hmdU repair, addressing how tight AP-site binding is overcome in cells.","evidence":"In vitro excision assays with purified proteins, EMSA, single-molecule analysis, immunofluorescence colocalization, and proximity ligation assay","pmids":["36971122"],"confidence":"High","gaps":["Whether UV-DDB stimulates SMUG1 on other substrates not tested","Generality across cell types and lesion contexts not established"]},{"year":null,"claim":"How SMUG1's glycosylase chemistry mechanistically couples to its RNA quality-control roles in rRNA and hTERC processing, and whether catalytic activity is required, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Catalytic-dead separation-of-function not reported in the corpus","Direct in vivo RNA base substrate not identified","Regulation distinguishing DNA-repair versus RNA-processing functions unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[1,2,3,4,8,9,15]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,3,4,9]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,11,15]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[12,17]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[12]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[12]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,12]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,2,5,8,16]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[12,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,14]}],"complexes":[],"partners":["DKC1","DDB1","DDB2","APE1","UNG"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q53HV7","full_name":"Single-strand selective monofunctional uracil DNA glycosylase","aliases":[],"length_aa":270,"mass_kda":29.9,"function":"Recognizes base lesions in the genome and initiates base excision DNA repair. Acts as a monofunctional DNA glycosylase specific for uracil (U) residues in DNA with a preference for single-stranded DNA substrates. The activity is greater toward mismatches (U/G) compared to matches (U/A). Excises uracil (U), 5-formyluracil (fU) and uracil derivatives bearing an oxidized group at C5 [5-hydroxyuracil (hoU) and 5-hydroxymethyluracil (hmU)] in ssDNA and dsDNA, but not analogous cytosine derivatives (5-hydroxycytosine and 5-formylcytosine), nor other oxidized bases. The activity is damage-specific and salt-dependent. The substrate preference is the following: ssDNA > dsDNA (G pair) = dsDNA (A pair) at low salt concentration, and dsDNA (G pair) > dsDNA (A pair) > ssDNA at high salt concentration","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q53HV7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMUG1","classification":"Not Classified","n_dependent_lines":169,"n_total_lines":1208,"dependency_fraction":0.13990066225165562},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMUG1","total_profiled":1310},"omim":[{"mim_id":"607753","title":"SINGLE-STRAND-SELECTIVE MONOFUNCTIONAL URACIL-DNA GLYCOSYLASE 1; SMUG1","url":"https://www.omim.org/entry/607753"},{"mim_id":"191525","title":"URACIL-DNA GLYCOSYLASE; UNG","url":"https://www.omim.org/entry/191525"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli fibrillar center","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SMUG1"},"hgnc":{"alias_symbol":["UNG3","FDG","HMUDG"],"prev_symbol":[]},"alphafold":{"accession":"Q53HV7","domains":[{"cath_id":"3.40.470.10","chopping":"47-237","consensus_level":"high","plddt":97.5115,"start":47,"end":237}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q53HV7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q53HV7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q53HV7-F1-predicted_aligned_error_v6.png","plddt_mean":92.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMUG1","jax_strain_url":"https://www.jax.org/strain/search?query=SMUG1"},"sequence":{"accession":"Q53HV7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q53HV7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q53HV7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q53HV7"}},"corpus_meta":[{"pmid":"9639291","id":"PMC_9639291","title":"FDG accumulation and tumor biology.","date":"1998","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/9639291","citation_count":271,"is_preprint":false},{"pmid":"28411336","id":"PMC_28411336","title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.","date":"2017","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/28411336","citation_count":204,"is_preprint":false},{"pmid":"9776283","id":"PMC_9776283","title":"Carbon-11-thymidine and FDG to measure therapy response.","date":"1998","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9776283","citation_count":171,"is_preprint":false},{"pmid":"11483530","id":"PMC_11483530","title":"Excision of deaminated cytosine from the vertebrate genome: role of the SMUG1 uracil-DNA glycosylase.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11483530","citation_count":165,"is_preprint":false},{"pmid":"19617326","id":"PMC_19617326","title":"123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.","date":"2009","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19617326","citation_count":127,"is_preprint":false},{"pmid":"11526119","id":"PMC_11526119","title":"Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11526119","citation_count":117,"is_preprint":false},{"pmid":"17283124","id":"PMC_17283124","title":"5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17283124","citation_count":114,"is_preprint":false},{"pmid":"12820976","id":"PMC_12820976","title":"Structure and specificity of the vertebrate anti-mutator uracil-DNA glycosylase SMUG1.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12820976","citation_count":112,"is_preprint":false},{"pmid":"12718543","id":"PMC_12718543","title":"Mammalian 5-formyluracil-DNA glycosylase. 2. Role of SMUG1 uracil-DNA glycosylase in repair of 5-formyluracil and other oxidized and deaminated base lesions.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12718543","citation_count":102,"is_preprint":false},{"pmid":"33277397","id":"PMC_33277397","title":"FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?","date":"2020","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33277397","citation_count":101,"is_preprint":false},{"pmid":"15902269","id":"PMC_15902269","title":"C --> T mutagenesis and gamma-radiation sensitivity due to deficiency in the Smug1 and Ung DNA glycosylases.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15902269","citation_count":100,"is_preprint":false},{"pmid":"17537817","id":"PMC_17537817","title":"Uracil-DNA glycosylases SMUG1 and UNG2 coordinate the initial steps of base excision repair by distinct mechanisms.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17537817","citation_count":95,"is_preprint":false},{"pmid":"24504054","id":"PMC_24504054","title":"Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.","date":"2014","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24504054","citation_count":90,"is_preprint":false},{"pmid":"22447450","id":"PMC_22447450","title":"Germline ablation of SMUG1 DNA glycosylase causes loss of 5-hydroxymethyluracil- and UNG-backup uracil-excision activities and increases cancer predisposition of Ung-/-Msh2-/- mice.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22447450","citation_count":86,"is_preprint":false},{"pmid":"26050942","id":"PMC_26050942","title":"The Basic Principles of FDG-PET/CT Imaging.","date":"2014","source":"PET clinics","url":"https://pubmed.ncbi.nlm.nih.gov/26050942","citation_count":81,"is_preprint":false},{"pmid":"22617239","id":"PMC_22617239","title":"New PET radiopharmaceuticals beyond FDG for brain tumor imaging.","date":"2012","source":"The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...","url":"https://pubmed.ncbi.nlm.nih.gov/22617239","citation_count":79,"is_preprint":false},{"pmid":"20651187","id":"PMC_20651187","title":"Characterization of T-cell lymphomas by FDG PET/CT.","date":"2010","source":"AJR. American journal of roentgenology","url":"https://pubmed.ncbi.nlm.nih.gov/20651187","citation_count":78,"is_preprint":false},{"pmid":"16407970","id":"PMC_16407970","title":"SMUG1 is able to excise uracil from immunoglobulin genes: insight into mutation versus repair.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16407970","citation_count":73,"is_preprint":false},{"pmid":"9747607","id":"PMC_9747607","title":"Imaging of mediastinal lymph nodes: CT, MR, and FDG PET.","date":"1998","source":"Radiographics : a review publication of the Radiological Society of North America, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/9747607","citation_count":73,"is_preprint":false},{"pmid":"23905617","id":"PMC_23905617","title":"FDG-PET imaging in HIV infection and tuberculosis.","date":"2013","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23905617","citation_count":69,"is_preprint":false},{"pmid":"17029639","id":"PMC_17029639","title":"Evaluation of NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 genes in familial colorectal cancer predisposition.","date":"2006","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17029639","citation_count":68,"is_preprint":false},{"pmid":"19910425","id":"PMC_19910425","title":"Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.","date":"2009","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19910425","citation_count":68,"is_preprint":false},{"pmid":"25453050","id":"PMC_25453050","title":"Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.","date":"2014","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25453050","citation_count":65,"is_preprint":false},{"pmid":"23246433","id":"PMC_23246433","title":"The human base excision repair enzyme SMUG1 directly interacts with DKC1 and contributes to RNA quality control.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23246433","citation_count":62,"is_preprint":false},{"pmid":"31868151","id":"PMC_31868151","title":"FDG PET/CT in the Staging of Lung Cancer.","date":"2020","source":"Current radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/31868151","citation_count":61,"is_preprint":false},{"pmid":"25239452","id":"PMC_25239452","title":"Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25239452","citation_count":59,"is_preprint":false},{"pmid":"21149494","id":"PMC_21149494","title":"18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.","date":"2010","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21149494","citation_count":56,"is_preprint":false},{"pmid":"27825431","id":"PMC_27825431","title":"PET Tracers Beyond FDG in Prostate Cancer.","date":"2016","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27825431","citation_count":53,"is_preprint":false},{"pmid":"25342384","id":"PMC_25342384","title":"Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas.","date":"2014","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25342384","citation_count":53,"is_preprint":false},{"pmid":"20814658","id":"PMC_20814658","title":"The use of FDG-PET to target tumors by radiotherapy.","date":"2010","source":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]","url":"https://pubmed.ncbi.nlm.nih.gov/20814658","citation_count":50,"is_preprint":false},{"pmid":"24927239","id":"PMC_24927239","title":"FDG-PET and amyloid-PET imaging: the diverging paths.","date":"2014","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24927239","citation_count":49,"is_preprint":false},{"pmid":"28775312","id":"PMC_28775312","title":"Uracil Accumulation and Mutagenesis Dominated by Cytosine Deamination in CpG Dinucleotides in Mice Lacking UNG and SMUG1.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28775312","citation_count":47,"is_preprint":false},{"pmid":"27090170","id":"PMC_27090170","title":"FDG-PET imaging in hematological malignancies.","date":"2016","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27090170","citation_count":42,"is_preprint":false},{"pmid":"15466595","id":"PMC_15466595","title":"Mutational analysis of the damage-recognition and catalytic mechanism of human SMUG1 DNA glycosylase.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15466595","citation_count":40,"is_preprint":false},{"pmid":"20448372","id":"PMC_20448372","title":"Non-FDG PET in the practice of oncology.","date":"2010","source":"Indian journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20448372","citation_count":40,"is_preprint":false},{"pmid":"28583274","id":"PMC_28583274","title":"Benign Bone Conditions That May Be FDG-avid and Mimic Malignancy.","date":"2017","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28583274","citation_count":38,"is_preprint":false},{"pmid":"24771041","id":"PMC_24771041","title":"Uracil excision by endogenous SMUG1 glycosylase promotes efficient Ig class switching and impacts on A:T substitutions during somatic mutation.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24771041","citation_count":38,"is_preprint":false},{"pmid":"22483865","id":"PMC_22483865","title":"Strikingly different properties of uracil-DNA glycosylases UNG2 and SMUG1 may explain divergent roles in processing of genomic uracil.","date":"2012","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/22483865","citation_count":36,"is_preprint":false},{"pmid":"26182964","id":"PMC_26182964","title":"Characterizing POEMS Syndrome with 18F-FDG PET/CT.","date":"2015","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26182964","citation_count":36,"is_preprint":false},{"pmid":"22043148","id":"PMC_22043148","title":"Lymphomatoid granulomatosis: CT and FDG-PET findings.","date":"2011","source":"Korean journal of radiology","url":"https://pubmed.ncbi.nlm.nih.gov/22043148","citation_count":35,"is_preprint":false},{"pmid":"9179213","id":"PMC_9179213","title":"Possible role of FDG-PET in the evaluation of urologic malignancies.","date":"1997","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9179213","citation_count":34,"is_preprint":false},{"pmid":"16557201","id":"PMC_16557201","title":"Cancer screening with FDG-PET.","date":"2006","source":"The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...","url":"https://pubmed.ncbi.nlm.nih.gov/16557201","citation_count":33,"is_preprint":false},{"pmid":"35418569","id":"PMC_35418569","title":"Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35418569","citation_count":32,"is_preprint":false},{"pmid":"24253812","id":"PMC_24253812","title":"Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy.","date":"2013","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/24253812","citation_count":32,"is_preprint":false},{"pmid":"31599488","id":"PMC_31599488","title":"FDG PET-CT in pediatric Langerhans cell histiocytosis.","date":"2019","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31599488","citation_count":31,"is_preprint":false},{"pmid":"27221817","id":"PMC_27221817","title":"FDG-PET characteristics of Hürthle cell and follicular adenomas.","date":"2016","source":"Annals of nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27221817","citation_count":31,"is_preprint":false},{"pmid":"35122511","id":"PMC_35122511","title":"Clozapine induces astrocyte-dependent FDG-PET hypometabolism.","date":"2022","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/35122511","citation_count":30,"is_preprint":false},{"pmid":"30617965","id":"PMC_30617965","title":"Obligatory role of endoplasmic reticulum in brain FDG uptake.","date":"2019","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/30617965","citation_count":29,"is_preprint":false},{"pmid":"20661166","id":"PMC_20661166","title":"Role of FDG PET-CT in recurrent renal cell carcinoma.","date":"2010","source":"Nuclear medicine communications","url":"https://pubmed.ncbi.nlm.nih.gov/20661166","citation_count":29,"is_preprint":false},{"pmid":"31412240","id":"PMC_31412240","title":"SMUG1 Promotes Telomere Maintenance through Telomerase RNA Processing.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31412240","citation_count":28,"is_preprint":false},{"pmid":"33569348","id":"PMC_33569348","title":"PET/CT in Multiple Myeloma: Beyond FDG.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33569348","citation_count":28,"is_preprint":false},{"pmid":"26280889","id":"PMC_26280889","title":"High resolution FDG-microPET of carotid atherosclerosis: plaque components underlying enhanced FDG uptake.","date":"2015","source":"The international journal of cardiovascular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/26280889","citation_count":28,"is_preprint":false},{"pmid":"34049163","id":"PMC_34049163","title":"FDG-PET in presymptomatic C9orf72 mutation carriers.","date":"2021","source":"NeuroImage. Clinical","url":"https://pubmed.ncbi.nlm.nih.gov/34049163","citation_count":27,"is_preprint":false},{"pmid":"18835277","id":"PMC_18835277","title":"Insights from xanthine and uracil DNA glycosylase activities of bacterial and human SMUG1: switching SMUG1 to UDG.","date":"2008","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18835277","citation_count":26,"is_preprint":false},{"pmid":"35241480","id":"PMC_35241480","title":"Signaling Pathways That Drive 18F-FDG Accumulation in Cancer.","date":"2022","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35241480","citation_count":26,"is_preprint":false},{"pmid":"34933889","id":"PMC_34933889","title":"The VISION Forward: Recognition and Implication of PSMA-/18F-FDG+ mCRPC.","date":"2021","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34933889","citation_count":26,"is_preprint":false},{"pmid":"19933624","id":"PMC_19933624","title":"18F-FDG PET/CT of transitional cell carcinoma.","date":"2009","source":"AJR. American journal of roentgenology","url":"https://pubmed.ncbi.nlm.nih.gov/19933624","citation_count":26,"is_preprint":false},{"pmid":"35422446","id":"PMC_35422446","title":"Dual-Tracer PET/CT Protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept.","date":"2022","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35422446","citation_count":25,"is_preprint":false},{"pmid":"22681674","id":"PMC_22681674","title":"Low-sensitivity FDG-PET studies: less common lung neoplasms.","date":"2012","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22681674","citation_count":24,"is_preprint":false},{"pmid":"22475427","id":"PMC_22475427","title":"FDG for therapy of metabolically active tumors.","date":"2012","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22475427","citation_count":24,"is_preprint":false},{"pmid":"12714953","id":"PMC_12714953","title":"Assessment of therapy response by FDG PET in pediatric patients.","date":"2003","source":"The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)","url":"https://pubmed.ncbi.nlm.nih.gov/12714953","citation_count":24,"is_preprint":false},{"pmid":"29195613","id":"PMC_29195613","title":"Interim FDG-PET Imaging in Lymphoma.","date":"2017","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29195613","citation_count":23,"is_preprint":false},{"pmid":"29051947","id":"PMC_29051947","title":"Pre-steady-state kinetic analysis of damage recognition by human single-strand selective monofunctional uracil-DNA glycosylase SMUG1.","date":"2017","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/29051947","citation_count":23,"is_preprint":false},{"pmid":"31508177","id":"PMC_31508177","title":"18F-FDG PET/CT IN DIFFERENTIATED THYROID CARCINOMA.","date":"2019","source":"Acta endocrinologica (Bucharest, Romania : 2005)","url":"https://pubmed.ncbi.nlm.nih.gov/31508177","citation_count":23,"is_preprint":false},{"pmid":"28861740","id":"PMC_28861740","title":"Gut microbiota and physiologic bowel 18F-FDG uptake.","date":"2017","source":"EJNMMI research","url":"https://pubmed.ncbi.nlm.nih.gov/28861740","citation_count":22,"is_preprint":false},{"pmid":"30941318","id":"PMC_30941318","title":"Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma.","date":"2019","source":"Annals of surgical treatment and research","url":"https://pubmed.ncbi.nlm.nih.gov/30941318","citation_count":21,"is_preprint":false},{"pmid":"37749301","id":"PMC_37749301","title":"From FDG and beyond: the evolving potential of nuclear medicine.","date":"2023","source":"Annals of nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37749301","citation_count":20,"is_preprint":false},{"pmid":"23253900","id":"PMC_23253900","title":"SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress.","date":"2012","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/23253900","citation_count":20,"is_preprint":false},{"pmid":"26140850","id":"PMC_26140850","title":"FDG-PET/CT findings in systemic mastocytosis: a French multicentre study.","date":"2015","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/26140850","citation_count":20,"is_preprint":false},{"pmid":"25475376","id":"PMC_25475376","title":"Multiple myeloma: 18F-FDG-PET/CT and diagnostic imaging.","date":"2015","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25475376","citation_count":18,"is_preprint":false},{"pmid":"17264775","id":"PMC_17264775","title":"Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer.","date":"2007","source":"Nuclear medicine communications","url":"https://pubmed.ncbi.nlm.nih.gov/17264775","citation_count":18,"is_preprint":false},{"pmid":"20823808","id":"PMC_20823808","title":"FDG-PET/CT in pediatric solid tumors.","date":"2010","source":"The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...","url":"https://pubmed.ncbi.nlm.nih.gov/20823808","citation_count":17,"is_preprint":false},{"pmid":"36376131","id":"PMC_36376131","title":"Interim FDG-PET/CT for Response Assessment of Lymphoma.","date":"2022","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36376131","citation_count":17,"is_preprint":false},{"pmid":"36911487","id":"PMC_36911487","title":"FDG-PET in Autoimmune Encephalitis: Utility, Pattern of Abnormalities, and Correlation with Autoantibodies.","date":"2022","source":"Annals of Indian Academy of Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36911487","citation_count":17,"is_preprint":false},{"pmid":"26944169","id":"PMC_26944169","title":"FDG-PET study of patients with Leigh syndrome.","date":"2016","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26944169","citation_count":17,"is_preprint":false},{"pmid":"25000313","id":"PMC_25000313","title":"FDG-PET imaging for Hodgkin lymphoma: current use and future applications.","date":"2014","source":"Clinical advances in hematology & oncology : H&O","url":"https://pubmed.ncbi.nlm.nih.gov/25000313","citation_count":17,"is_preprint":false},{"pmid":"27666620","id":"PMC_27666620","title":"The correlation between FDG uptake and biological molecular markers in pancreatic cancer patients.","date":"2016","source":"European journal of radiology","url":"https://pubmed.ncbi.nlm.nih.gov/27666620","citation_count":17,"is_preprint":false},{"pmid":"33671338","id":"PMC_33671338","title":"The Multiple Cellular Roles of SMUG1 in Genome Maintenance and Cancer.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33671338","citation_count":16,"is_preprint":false},{"pmid":"30554355","id":"PMC_30554355","title":"Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation.","date":"2018","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/30554355","citation_count":16,"is_preprint":false},{"pmid":"34242840","id":"PMC_34242840","title":"Hypermetabolic pulmonary lesions on FDG-PET/CT: Tularemia or neoplasia?","date":"2021","source":"Infectious diseases now","url":"https://pubmed.ncbi.nlm.nih.gov/34242840","citation_count":16,"is_preprint":false},{"pmid":"28512558","id":"PMC_28512558","title":"FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management.","date":"2017","source":"Mediterranean journal of hematology and infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28512558","citation_count":16,"is_preprint":false},{"pmid":"32894535","id":"PMC_32894535","title":"Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32894535","citation_count":15,"is_preprint":false},{"pmid":"24695005","id":"PMC_24695005","title":"Reproducibility of FDG PET based metabolic tumor volume measurements and of their FDG distribution within.","date":"2014","source":"The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...","url":"https://pubmed.ncbi.nlm.nih.gov/24695005","citation_count":15,"is_preprint":false},{"pmid":"19015450","id":"PMC_19015450","title":"Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer.","date":"2008","source":"Archives of otolaryngology--head & neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19015450","citation_count":15,"is_preprint":false},{"pmid":"33430019","id":"PMC_33430019","title":"RNA Metabolism Guided by RNA Modifications: The Role of SMUG1 in rRNA Quality Control.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/33430019","citation_count":14,"is_preprint":false},{"pmid":"28318446","id":"PMC_28318446","title":"Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque?","date":"2017","source":"Radiology","url":"https://pubmed.ncbi.nlm.nih.gov/28318446","citation_count":14,"is_preprint":false},{"pmid":"15923438","id":"PMC_15923438","title":"FDG-PET in the management of germ cell tumor.","date":"2005","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15923438","citation_count":14,"is_preprint":false},{"pmid":"15696855","id":"PMC_15696855","title":"FDG-PET scanning in the diagnosis of gastrointestinal cancers.","date":"2004","source":"Scandinavian journal of gastroenterology. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/15696855","citation_count":14,"is_preprint":false},{"pmid":"31024918","id":"PMC_31024918","title":"Interest of FDG-PET in the Management of Mantle Cell Lymphoma.","date":"2019","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31024918","citation_count":13,"is_preprint":false},{"pmid":"33822711","id":"PMC_33822711","title":"Clinical and FDG-PET/CT correlates in patients with polymyalgia rheumatica.","date":"2021","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/33822711","citation_count":13,"is_preprint":false},{"pmid":"26544161","id":"PMC_26544161","title":"FDG-PET/CT in abdominal post-transplant lymphoproliferative disease.","date":"2015","source":"The British journal of radiology","url":"https://pubmed.ncbi.nlm.nih.gov/26544161","citation_count":13,"is_preprint":false},{"pmid":"26941858","id":"PMC_26941858","title":"Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma.","date":"2015","source":"Nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/26941858","citation_count":13,"is_preprint":false},{"pmid":"27280732","id":"PMC_27280732","title":"Monitoring Vasculitis with 18F-FDG PET.","date":"2016","source":"The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...","url":"https://pubmed.ncbi.nlm.nih.gov/27280732","citation_count":12,"is_preprint":false},{"pmid":"36575286","id":"PMC_36575286","title":"FDG-PET findings associated with various medical procedures and treatments.","date":"2022","source":"Japanese journal of radiology","url":"https://pubmed.ncbi.nlm.nih.gov/36575286","citation_count":12,"is_preprint":false},{"pmid":"38997880","id":"PMC_38997880","title":"Predictive [18F]-FDG PET/CT-Based Radiogenomics Modelling of Driver Gene Mutations in Non-small Cell Lung Cancer.","date":"2024","source":"Academic radiology","url":"https://pubmed.ncbi.nlm.nih.gov/38997880","citation_count":12,"is_preprint":false},{"pmid":"30456190","id":"PMC_30456190","title":"The use of F-FDG PET/CT in testicular cancer.","date":"2018","source":"Translational andrology and urology","url":"https://pubmed.ncbi.nlm.nih.gov/30456190","citation_count":12,"is_preprint":false},{"pmid":"32701815","id":"PMC_32701815","title":"Nivolumab-Induced Periaortitis Demonstrated by FDG PET/CT.","date":"2020","source":"Clinical nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32701815","citation_count":12,"is_preprint":false},{"pmid":"36971122","id":"PMC_36971122","title":"UV-DDB stimulates the activity of SMUG1 during base excision repair of 5-hydroxymethyl-2'-deoxyuridine moieties.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36971122","citation_count":11,"is_preprint":false},{"pmid":"22890522","id":"PMC_22890522","title":"FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.","date":"2012","source":"Wiener medizinische Wochenschrift (1946)","url":"https://pubmed.ncbi.nlm.nih.gov/22890522","citation_count":11,"is_preprint":false},{"pmid":"35803770","id":"PMC_35803770","title":"A Role of Non-FDG Tracers in Lung Cancer?","date":"2022","source":"Seminars in nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35803770","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52325,"output_tokens":5486,"usd":0.119633,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13948,"output_tokens":5530,"usd":0.103995,"stage2_stop_reason":"end_turn"},"total_usd":0.223628,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"SMUG1 was identified as the major uracil-DNA glycosylase activity in UNG-deficient mice, functioning as the primary backup enzyme for repair of deaminated cytosine. SMUG1 is present at similar levels in non-proliferating and proliferating tissues, indicating a replication-independent role in DNA repair, distinct from UNG which localizes to replication foci.\",\n      \"method\": \"Specific neutralizing antibodies used to identify SMUG1 activity in Ung-/- mouse cells and tissues; subcellular localization by cell fractionation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal antibody neutralization assay in knockout mice, replicated finding consistent with genetic knockout data from multiple labs\",\n      \"pmids\": [\"11483530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human SMUG1 (hSMUG1) was identified as identical to HMUDG (5-hydroxymethyluracil DNA N-glycosylase), demonstrating that SMUG1 excises 5-hydroxymethyluracil (5hmUra) from DNA with ~20x the specific activity of the most purified bovine HMUDG fraction.\",\n      \"method\": \"Protein purification from calf thymus, SDS-PAGE renaturation assay, mass spectrometry peptide identification, recombinant GST-fusion protein expression and in vitro enzymatic assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with recombinant protein plus mass spectrometry identification, rigorous biochemical characterization\",\n      \"pmids\": [\"11526119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of SMUG1 complexed with DNA and base-excision products revealed a more invasive interaction with dsDNA than other UDGs, and an elegant water displacement/replacement mechanism that allows SMUG1 to exclude thymine while accepting 5-hydroxymethyluracil (HmU) as a substrate. SMUG1 is specialized for antimutational uracil excision and also excises the oxidation-damage product HmU.\",\n      \"method\": \"X-ray crystallography of SMUG1-DNA complex\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with bound substrate/product providing direct mechanistic insight into substrate discrimination\",\n      \"pmids\": [\"12820976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Rat and human SMUG1 excise 5-formyluracil (fU), uracil (U), 5-hydroxyuracil (hoU), and 5-hydroxymethyluracil (hmU) from both single-stranded and double-stranded DNA, but not analogous cytosine derivatives (5-hydroxycytosine, 5-formylcytosine) or other oxidized damage. hSMUG1 antibodies neutralized fU, hmU, and hoU activities in HeLa cell extracts, confirming SMUG1 is the primary repair enzyme for this subset of oxidized pyrimidines.\",\n      \"method\": \"Recombinant protein expression of rat and human SMUG1, in vitro substrate specificity assays with various modified bases in ss and dsDNA, antibody neutralization of HeLa cell extract activity\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant enzymes plus antibody neutralization in cell extracts, multiple orthogonal methods\",\n      \"pmids\": [\"12718543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Site-directed mutagenesis of hSMUG1 identified crucial residues for catalysis and damage recognition: Asn85 and His239 are required for N-glycosidic bond hydrolysis; Phe98 mediates pi-pi stacking discrimination of pyrimidine rings; Asn163 forms specific hydrogen bonds to the Watson-Crick face of the base; and Gly87-Met91 loop enables recognition of C5 substituents through water-bridged (uracil) or direct (hoU, hmU, fU) hydrogen bonds.\",\n      \"method\": \"Site-directed mutagenesis of hSMUG1 combined with in vitro activity assays for multiple substrates (U, hoU, hmU, fU) and homology modeling based on Xenopus laevis SMUG1 structure\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — active-site mutagenesis with functional validation for multiple residues across multiple substrates, supported by structural modeling\",\n      \"pmids\": [\"15466595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"siRNA-mediated silencing of Smug1 in mouse embryo fibroblasts generates a mutator phenotype with increased C:G to T:A transitions. Cells deficient in both Smug1 and Ung show an additive 10-fold increase in spontaneous C:G to T:A transitions at non-CpG sites, demonstrating that these enzymes have distinct and non-redundant roles. Smug1-deficient cells are also hypersensitive to ionizing radiation, revealing a role of SMUG1 in repair of oxidative cytosine lesions.\",\n      \"method\": \"Stable siRNA-mediated knockdown of Smug1, spontaneous mutation frequency measurement (lacZ reporter), double-mutant epistasis analysis (Ung-/- Smug1 knockdown), ionizing radiation sensitivity assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with loss-of-function and defined mutational phenotype, double-mutant analysis across two independent labs\",\n      \"pmids\": [\"15902269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SMUG1, if overexpressed, can partially substitute for UNG in antibody diversification (somatic hypermutation and class switch recombination), but SMUG1 plays little natural role in antibody diversification because it is diminishingly expressed during B-cell activation. Even when overexpressed, SMUG1 favors conventional repair of U:G lesions rather than diversification, distinguishing it from UNG which associates with replication sites.\",\n      \"method\": \"SMUG1 overexpression in DT40 B cells and transgenic mice; somatic hypermutation pattern analysis; isotype switching assays in SMUG-transgenic msh2-/- ung-/- mice; expression analysis during B-cell activation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with transgenic overexpression, multiple functional readouts (SHM patterns, isotype switching), consistent with biology from multiple labs\",\n      \"pmids\": [\"16407970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SMUG1 (but not UNG) excises 5-fluorouracil (FU) incorporated into DNA and protects against FU cytotoxicity. Accumulation of FU in the genome, rather than uracil excision, is the predominant cause of FU cytotoxicity in mammalian cells.\",\n      \"method\": \"Gene-targeted cell lines defective in UNG, SMUG1, or both; FU cytotoxicity assays; genomic FU/uracil incorporation measurements\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockouts with defined biochemical and cytotoxicity phenotypes, multiple orthogonal methods\",\n      \"pmids\": [\"17283124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SMUG1 and UNG2 coordinate the initial steps of base excision repair by distinct mechanisms: UNG2 stimulates AP-site cleavage by APE1 and lacks product-binding capacity enabling rapid turnover; SMUG1 binds tightly to AP-sites and inhibits AP-site cleavage by AP-endonucleases. A specific motif important for AP-site product binding was identified in SMUG1; mutations in this motif increase catalytic turnover by reducing product binding.\",\n      \"method\": \"In vitro AP-site binding and cleavage assays; E. coli complementation assay; site-directed mutagenesis of AP-site binding motif; comparison of UNG2 and SMUG1 enzymatic properties\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis and multiple orthogonal biochemical assays in a single rigorous study\",\n      \"pmids\": [\"17537817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SMUG1 (bacterial ortholog from Geobacter metallireducens and human SMUG1) are not only uracil-DNA glycosylases but also xanthine DNA glycosylases (XDGs). Mutational analysis identified M57 and H210 as critical for both XDG and UDG activities via interactions with the C2 carbonyl oxygen; G60Y abolishes both activities by blocking base entry to the binding pocket; G63P switches Gme SMUG1 to an exclusive UDG by altering active-site loop flexibility.\",\n      \"method\": \"Site-directed mutagenesis of bacterial and human SMUG1, in vitro XDG and UDG activity assays on ss and dsDNA substrates, molecular dynamics simulations\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis with in vitro enzymatic reconstitution and MD simulations providing mechanistic insight\",\n      \"pmids\": [\"18835277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Targeted inactivation of mouse Smug1 ablates nearly all hmU-DNA excision activity in tissue extracts and renders embryo fibroblasts resistant to 5-hydroxymethyldeoxyuridine toxicity. Combined Smug1/Ung knockout leads to loss of nearly all detectable uracil excision activity, confirming SMUG1 as the dominant glycosylase for hmU-excision and major UNG-backup for U-excision in mice.\",\n      \"method\": \"Knockout mouse generation, biochemical assay of tissue extracts, 5-hydroxymethyldeoxyuridine cytotoxicity assay in embryo fibroblasts, double-knockout epistasis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with biochemical validation and epistasis analysis in multiple tissue types\",\n      \"pmids\": [\"22447450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SMUG1 is predominantly double-strand-specific under physiological salt conditions (in the presence of Mg2+ and monovalent salts), whereas UNG2 efficiently removes uracil from both ss and dsDNA. Uracil in AID hotspot sequences is removed 200-fold more efficiently from ssDNA by UNG2 than by SMUG1, explaining why SMUG1 cannot replace UNG2 in antibody diversification despite not being excluded from Ig loci.\",\n      \"method\": \"In vitro UDG activity assays under varying ionic conditions with ss and dsDNA substrates; measurement of sequence preference for AID hotspot sequences\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution with systematic substrate variation, provides mechanistic explanation for prior genetic observations\",\n      \"pmids\": [\"22483865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SMUG1 interacts with the pseudouridine synthase Dyskerin (DKC1) and colocalizes with DKC1 in nucleoli and Cajal bodies. SMUG1 has enzymatic activity on single-stranded RNA containing 5-hydroxymethyldeoxyuridine. SMUG1 associates with the 47S rRNA precursor, and depletion of SMUG1 reduces mature rRNA levels with concomitant increase in polyadenylated rRNA and accumulation of 5-hydroxymethyluridine in rRNA.\",\n      \"method\": \"Co-immunoprecipitation (SMUG1-DKC1 interaction), colocalization by immunofluorescence, in vitro RNA glycosylase activity assay, RNA immunoprecipitation (47S rRNA), siRNA depletion with rRNA maturation analysis and 5-hydroxymethyluridine quantification\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vitro RNA activity assay, and functional depletion phenotype with multiple orthogonal methods in one study\",\n      \"pmids\": [\"23246433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of SMUG1 (but not UNG) leads to >2-fold increased sensitivity to 5-fluorouracil specifically after drug removal (recovery phase), associated with prolonged S-phase arrest, transient increase in DNA double-strand breaks, and altered CHK1 phosphorylation, indicating SMUG1 has a role in resumption of replication following 5-FU treatment.\",\n      \"method\": \"SMUG1 and UNG knockdown in human cell lines, 5-FU sensitivity assays (continuous vs. 24h then recovery), cell cycle analysis, comet assay, CHK1 phosphorylation by immunoblot\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean knockdown with multiple phenotypic readouts but single lab, mechanistic pathway placement by epistasis\",\n      \"pmids\": [\"23253900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endogenous SMUG1 contributes to immunoglobulin class switching in Ung-/- mice, with most residual class switching in Ung-/- mice depending on SMUG1. In vitro switching to IgG1 and serum IgG3, IgG2b, and IgA are greatly diminished in Ung-/- Smug1-/- mice. SMUG1 deficiency in an Ung-/- background further reduces somatic hypermutation at A:T base pairs.\",\n      \"method\": \"Double-knockout mice (Ung-/- Smug1-/-), in vitro class switching assays, serum immunoglobulin isotype quantification, somatic hypermutation pattern analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in double-knockout mice with multiple functional readouts (switching assays, serum isotypes, SHM patterns)\",\n      \"pmids\": [\"24771041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Pre-steady-state kinetic analysis revealed the mechanism of damaged base recognition by hSMUG1: the enzyme undergoes nonspecific DNA binding followed by specific damaged-base recognition using a 'wedge' strategy for lesion search. SMUG1 is rate-limited by release from the AP-site product (tight product binding confirmed), with the true catalytic rate faster than kcat measured at steady state. Conformational changes in both enzyme (Trp fluorescence) and DNA (2-aminopurine fluorescence and FRET) were detected during recognition.\",\n      \"method\": \"Stopped-flow fluorescence spectroscopy using Trp fluorescence, 2-aminopurine fluorescence, and FRET with dU:dG DNA substrate; pre-steady-state kinetic analysis\",\n      \"journal\": \"Molecular bioSystems\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous pre-steady-state kinetics with multiple orthogonal fluorescence methods revealing mechanistic steps of substrate recognition\",\n      \"pmids\": [\"29051947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In Smug1-/- mice, 5-hydroxymethyluracil accumulates in genomic DNA (up to 26-fold in brain, correlating with 5-hydroxymethylcytosine levels), while uracil does not accumulate. Ung-/- Smug1-/- mice show synergistic uracil accumulation (up to 25-fold). Whole genome sequencing of double-deficient tumors reveals C to T transitions primarily at CpG sequences, identifying mutational signatures of combined UNG/SMUG1 deficiency.\",\n      \"method\": \"Knockout mice (single and double), genomic 5-hydroxymethyluracil and uracil quantification by mass spectrometry, whole-genome sequencing of tumors for mutational signature analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with quantitative biochemical substrate measurement and genome-wide mutation analysis; multiple complementary methods\",\n      \"pmids\": [\"28775312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMUG1 interacts with the telomeric RNA component (hTERC) and is required for co-transcriptional processing of nascent hTERC into mature form. SMUG1 regulates base modifications in hTERC in a region between the CR4/CR5 domain and H box; loss of SMUG1 leads to reduced DKC1 binding to hTERC, accumulation of 3'-polyadenylated and 3'-extended hTERC intermediates degraded by an EXOSC10-independent pathway, and telomerase deficiency leading to impaired bone marrow proliferation in Smug1-knockout mice.\",\n      \"method\": \"RNA immunoprecipitation (SMUG1-hTERC interaction), DKC1-hTERC binding assay in SMUG1-depleted cells, hTERC processing intermediate analysis by northern blot/RT-PCR, telomerase activity assay, Smug1-knockout mouse bone marrow proliferation analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (RIP, binding assays, RNA processing analysis, telomerase activity, in vivo knockout phenotype) in single rigorous study\",\n      \"pmids\": [\"31412240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UV-DDB (UV-damaged DNA-binding protein, consisting of DDB1 and DDB2 subunits) stimulates SMUG1 excision activity on 5-hmdU substrates by 4-5-fold in vitro, displaces SMUG1 from abasic site products (EMSA), and decreases SMUG1 half-life on DNA ~8-fold (single-molecule analysis). In cells, DDB2 and SMUG1 form discrete co-localizing foci after 5-hmdU treatment and exhibit transient interaction by proximity ligation assay.\",\n      \"method\": \"In vitro biochemical excision assay with purified proteins, EMSA, single-molecule analysis, immunofluorescence colocalization, proximity ligation assay, siRNA knockdown with poly(ADP-ribose) accumulation readout\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified proteins plus multiple orthogonal cellular validation methods including single-molecule imaging\",\n      \"pmids\": [\"36971122\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMUG1 is a base excision repair glycosylase that excises uracil, 5-hydroxymethyluracil, 5-hydroxyuracil, 5-formyluracil, and 5-fluorouracil from DNA (primarily double-stranded) via a wedge-based lesion search mechanism, with tight AP-site product binding that inhibits APE1 and limits turnover; it also acts on RNA substrates, interacts with the DKC1 pseudouridine synthase to regulate rRNA quality control and hTERC maturation for telomerase biogenesis, is stimulated by UV-DDB during 5-hmdU repair, and plays non-redundant roles with UNG in suppressing C-to-T mutagenesis, processing 5-FU incorporated into DNA, and contributing to immunoglobulin class switching as a backup to UNG.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMUG1 is a base excision repair DNA glycosylase that initiates antimutational removal of uracil and oxidized pyrimidines, serving as the principal replication-independent backup to UNG for repair of deaminated cytosine [#0, #5]. It excises uracil, 5-hydroxymethyluracil, 5-hydroxyuracil, and 5-formyluracil from DNA, while excluding thymine and analogous cytosine derivatives, and additionally acts as a xanthine-DNA glycosylase [#1, #3, #9]. Crystallography and active-site mutagenesis define how SMUG1 reads the lesion: an invasive interaction with double-stranded DNA, a water displacement/replacement strategy that admits C5-substituted uracils but excludes thymine, and defined catalytic and recognition residues (Asn85, His239, Phe98, Asn163, and the Gly87-Met91 loop) [#2, #4]. Pre-steady-state kinetics establish a wedge-based lesion-search mechanism in which catalysis is rate-limited by tight binding to the abasic-site product, a property that lets SMUG1 inhibit AP-site cleavage by APE1 and that distinguishes it from rapid-turnover UNG2 [#8, #15]; under physiological salt SMUG1 is predominantly double-strand specific, explaining its limited capacity to substitute for UNG in single-strand contexts [#11]. Genetically, SMUG1 and UNG have non-redundant roles in suppressing C-to-T mutagenesis and in preventing genomic accumulation of 5-hydroxymethyluracil, with combined deficiency producing synergistic uracil accumulation and CpG-biased mutational signatures [#5, #10, #16]. SMUG1 also processes 5-fluorouracil incorporated into DNA, protecting against its cytotoxicity and supporting replication recovery after drug exposure [#7, #13], and contributes to immunoglobulin class switching and A:T somatic hypermutation as a backup to UNG [#6, #14]. Beyond DNA, SMUG1 functions in RNA quality control through interaction with the pseudouridine synthase DKC1, governing rRNA maturation and co-transcriptional processing of the telomerase RNA component hTERC required for telomerase biogenesis [#12, #17]. Its 5-hmdU excision is stimulated by UV-DDB, which displaces SMUG1 from abasic products to relieve product inhibition [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established SMUG1 as the major UNG-independent uracil-excision activity in vivo, defining a replication-independent backup arm of cytosine-deamination repair distinct from replication-coupled UNG.\",\n      \"evidence\": \"Antibody neutralization of glycosylase activity in Ung-/- mouse cells and subcellular fractionation\",\n      \"pmids\": [\"11483530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the full lesion spectrum\", \"Did not establish whether the backup role suffices to prevent mutagenesis\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified SMUG1 as the enzyme behind HMUDG activity, extending its substrate range beyond uracil to the oxidation product 5-hydroxymethyluracil.\",\n      \"evidence\": \"Protein purification, mass spectrometry, and recombinant enzyme assays from calf thymus/human SMUG1\",\n      \"pmids\": [\"11526119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish in vivo importance of hmU excision\", \"Strandedness preference not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the structural basis for substrate discrimination, showing how SMUG1 excludes thymine yet accepts C5-modified uracils via a water displacement mechanism and an unusually invasive dsDNA interaction.\",\n      \"evidence\": \"X-ray crystallography of SMUG1-DNA base-excision product complex; recombinant rat/human enzyme substrate-specificity assays with antibody neutralization in HeLa extracts\",\n      \"pmids\": [\"12820976\", \"12718543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic residue assignments not yet functionally tested\", \"Kinetics of recognition and product release unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the catalytic and recognition residues, mechanistically explaining how SMUG1 hydrolyzes the glycosidic bond and reads diverse C5 substituents.\",\n      \"evidence\": \"Site-directed mutagenesis of hSMUG1 with multi-substrate activity assays and homology modeling\",\n      \"pmids\": [\"15466595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address product binding/turnover kinetics\", \"Modeling rather than human crystal structure\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated that SMUG1 and UNG are genetically non-redundant in suppressing C-to-T transitions and that SMUG1 also defends against oxidative cytosine lesions.\",\n      \"evidence\": \"Stable siRNA knockdown in mouse fibroblasts, lacZ mutation frequency, Ung-/- double-mutant epistasis, and ionizing-radiation sensitivity\",\n      \"pmids\": [\"15902269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Knockdown rather than complete knockout\", \"Molecular identity of the relevant oxidative cytosine lesion not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Clarified why SMUG1 contributes little to antibody diversification under physiological conditions despite being able to substitute for UNG when overexpressed.\",\n      \"evidence\": \"SMUG1 overexpression in DT40 cells and transgenic mice; SHM/class-switch assays and B-cell expression analysis\",\n      \"pmids\": [\"16407970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the biochemical basis for the preference for conventional repair\", \"Endogenous contribution in Ung-/- not yet quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed SMUG1 uniquely processes genomic 5-fluorouracil and that genomic FU incorporation, not uracil excision, drives FU cytotoxicity, linking SMUG1 to chemotherapy response.\",\n      \"evidence\": \"Gene-targeted UNG/SMUG1/double-deficient cell lines, FU cytotoxicity assays, and genomic FU/uracil measurements\",\n      \"pmids\": [\"17283124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream repair steps after FU excision not defined\", \"Did not address replication recovery dynamics\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the divergent BER initiation logic of SMUG1 versus UNG2, showing SMUG1 binds AP-site products tightly and inhibits APE1 cleavage while UNG2 promotes rapid turnover.\",\n      \"evidence\": \"In vitro AP-site binding/cleavage assays, E. coli complementation, and mutagenesis of an AP-site-binding motif\",\n      \"pmids\": [\"17537817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular factors relieving product inhibition not identified\", \"Physiological consequence of APE1 inhibition unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended SMUG1's catalytic repertoire to xanthine excision and mapped the active-site determinants distinguishing UDG from XDG activity.\",\n      \"evidence\": \"Mutagenesis of bacterial and human SMUG1, in vitro UDG/XDG assays, and molecular dynamics simulations\",\n      \"pmids\": [\"18835277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of xanthine excision not established\", \"Frequency of xanthine lesions in genomic DNA not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Genetic ablation in mice confirmed SMUG1 as the dominant hmU-excising glycosylase and the major UNG backup for uracil, validating prior biochemical assignments in vivo.\",\n      \"evidence\": \"Single and double Smug1/Ung knockout mice, tissue extract glycosylase assays, and 5-hmdU cytotoxicity in fibroblasts\",\n      \"pmids\": [\"22447450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify genomic lesion accumulation\", \"Tissue-specific contributions not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided the biochemical explanation for SMUG1's limited role at Ig loci by showing it is predominantly double-strand specific under physiological salt, unlike UNG2 on ssDNA.\",\n      \"evidence\": \"In vitro UDG assays under varying ionic conditions with ss/dsDNA and AID-hotspot substrates\",\n      \"pmids\": [\"22483865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test whether cellular cofactors alter strand preference\", \"In vivo strand context at lesion sites not measured\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed an RNA-directed function for SMUG1 in ribosomal RNA quality control via interaction with DKC1, expanding its role beyond DNA repair.\",\n      \"evidence\": \"Reciprocal Co-IP and colocalization with DKC1, in vitro ssRNA glycosylase assay, 47S rRNA RIP, and siRNA depletion with rRNA maturation/5-hmU readouts\",\n      \"pmids\": [\"23246433\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA substrate base in vivo not pinpointed\", \"Mechanistic coupling between glycosylase activity and rRNA processing unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked SMUG1 to replication recovery after 5-FU exposure, distinguishing a recovery-phase role from acute uracil/FU excision.\",\n      \"evidence\": \"SMUG1/UNG knockdown in human cells, recovery-phase FU sensitivity, cell-cycle and comet assays, and CHK1 phosphorylation immunoblot\",\n      \"pmids\": [\"23253900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, knockdown only\", \"Mechanistic link between SMUG1 and CHK1/replication checkpoint not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Quantified SMUG1's endogenous contribution to immunoglobulin class switching and A:T hypermutation as the principal residual activity in Ung-/- mice.\",\n      \"evidence\": \"Ung-/- Smug1-/- double-knockout mice, in vitro switching assays, serum isotype quantification, and SHM pattern analysis\",\n      \"pmids\": [\"24771041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular step at which SMUG1 acts in switching\", \"Strand-specific processing at switch regions not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the kinetic mechanism of lesion recognition, establishing a wedge-based search and product-release-limited catalysis with detectable enzyme and DNA conformational changes.\",\n      \"evidence\": \"Stopped-flow Trp/2-aminopurine fluorescence and FRET pre-steady-state kinetics on dU:dG DNA\",\n      \"pmids\": [\"29051947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify factors that accelerate product release in cells\", \"Recognition kinetics for oxidized substrates not measured\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established the in vivo lesion-specific consequences of SMUG1 loss, with selective genomic 5-hmU accumulation and synergistic uracil buildup and CpG-biased mutational signatures upon combined UNG loss.\",\n      \"evidence\": \"Single/double knockout mice, mass-spectrometric genomic lesion quantification, and whole-genome sequencing of tumors\",\n      \"pmids\": [\"28775312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Origin of CpG-biased mutations not mechanistically dissected\", \"Tissue-specific tumor risk not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the RNA role to telomerase biogenesis, showing SMUG1 is required for co-transcriptional hTERC processing and DKC1 binding, with telomerase deficiency and impaired bone marrow proliferation on its loss.\",\n      \"evidence\": \"hTERC RIP, DKC1-hTERC binding in SMUG1-depleted cells, processing-intermediate analysis, telomerase activity assays, and Smug1-knockout mouse bone marrow phenotype\",\n      \"pmids\": [\"31412240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether catalytic glycosylase activity is required for hTERC processing unresolved\", \"Identity of the modified bases regulating hTERC not fully defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified UV-DDB as a stimulatory partner that relieves SMUG1 product inhibition during 5-hmdU repair, addressing how tight AP-site binding is overcome in cells.\",\n      \"evidence\": \"In vitro excision assays with purified proteins, EMSA, single-molecule analysis, immunofluorescence colocalization, and proximity ligation assay\",\n      \"pmids\": [\"36971122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether UV-DDB stimulates SMUG1 on other substrates not tested\", \"Generality across cell types and lesion contexts not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SMUG1's glycosylase chemistry mechanistically couples to its RNA quality-control roles in rRNA and hTERC processing, and whether catalytic activity is required, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Catalytic-dead separation-of-function not reported in the corpus\", \"Direct in vivo RNA base substrate not identified\", \"Regulation distinguishing DNA-repair versus RNA-processing functions unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [1, 2, 3, 4, 8, 9, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 3, 4, 9]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 11, 15]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [12, 17]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 2, 5, 8, 16]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [12, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DKC1\", \"DDB1\", \"DDB2\", \"APE1\", \"UNG\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}